Company news
Quince Therapeutics, Inc. news in 2023
Quince Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
October 22, 2023
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
September 27, 2023
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
September 5, 2023
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
July 23, 2023
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
April 4, 2023
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
March 21, 2023
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
January 29, 2023
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
January 26, 2023
Decks in 2023
- Merger or Acquisition (July 2023)
Merger or acquisition · 19 slides · Jul 24, 2023